Citations (400)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (63)
Michael J. Silverman. (2023) A recovery-oriented critical interpretive synthesis of withdrawal tools in the Journal of Substance Use. Journal of Substance Use 28:5, pages 766-776.
Read now
Read now
Simeon D. Kimmel, Kristina T. Phillips, Bradley J. Anderson & Michael D. Stein. (2022) Characteristics associated with motivation to stop substance use and improve skin and needle hygiene among hospitalized patients who inject drugs. Substance Abuse 43:1, pages 878-883.
Read now
Read now
Anupam Ankit, Basudeb Das, Pranjal Dey, Khitish Kumar Kshitiz & Christoday Raja Jayant Khess. (2022) Efficacy of continuous theta burst stimulation - repetitive trancranial magnetic stimulation on the orbito frontal cortex as an adjunct to naltrexone in patients of opioid use disorder and its correlation with serum BDNF levels: a sham-controlled study. Journal of Addictive Diseases 40:3, pages 373-381.
Read now
Read now
Martha Ooms, Hendrik G. Roozen, Juul H. Willering, Wobbe P. Zijlstra, Ranne de Waart & Anna E. Goudriaan. (2021) Effects of Multiple Detoxifications on Withdrawal Symptoms, Psychiatric Distress and Alcohol-Craving in Patients with an Alcohol Use Disorder. Behavioral Medicine 47:4, pages 296-310.
Read now
Read now
Michael Guarnieri, Jayanidhi Kedda & Betty Tyler. (2021) Buprenorphine implants: a model for expedited development and approval of new drugs. Current Medical Research and Opinion 37:1, pages 83-88.
Read now
Read now
Richard F Howard, Tatjana Radic, Melanie Sohns, Mariëlle Eerdekens & Andrea Waßmuth. (2020) Tapentadol Prolonged Release for Long-Term Treatment of Pain in Children. Journal of Pain Research 13, pages 3157-3170.
Read now
Read now
Mohammad Sibai, Kaitlyn Mishlen, Edward V. Nunes, Frances R. Levin, John J. Mariani & Adam Bisaga. (2020) A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder. The American Journal of Drug and Alcohol Abuse 46:3, pages 289-296.
Read now
Read now
Hance Clarke, Aliza Weinrib, Yuvaraj Kotteeswaran, Joel Katz, Alvis Yu & Robert Tanguay. (2020) Remote buprenorphine-naloxone initiation as an essential service for people with chronic pain and opioid dependence during the COVID-19 pandemic: Case reports, clinical pathways, and implications for the future. Canadian Journal of Pain 4:1, pages 224-235.
Read now
Read now
Walter Ling, Vijay R Nadipelli, Caitlyn T Solem, David Farabee, Naoko A Ronquest, Brian Perrochet, Susan M Learned, Chinmay G Deshpande & Christian Heidbreder. (2019) Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment. Substance Abuse and Rehabilitation 10, pages 13-21.
Read now
Read now
Sergio D Bergese, Marek Brzezinski, Gregory B Hammer, Timothy L Beard, Peter H Pan, Sharon E Mace, Richard D Berkowitz, Kristina Cochrane, Linda Wase, Harold S Minkowitz & Ashraf S Habib. (2019) ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The µ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy. Journal of Pain Research 12, pages 3113-3126.
Read now
Read now
Mikito Kawamata, Masako Iseki, Mamoru Kawakami, Shoji Yabuki, Takuma Sasaki, Mitsuhiro Ishida, Atsushi Nishiyori, Hideaki Hida & Shin-ichi Kikuchi. (2019) Efficacy And Safety Of Controlled-Release Oxycodone For The Management Of Moderate-To-Severe Chronic Non-Cancer Pain In Japanese Patients: Results From An Open-Label Study. Journal of Pain Research 12, pages 3423-3436.
Read now
Read now
Richard L Rauck, Neal E Slatkin, Nancy Stambler & Robert J Israel. (2019) Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. Journal of Pain Research 12, pages 139-150.
Read now
Read now
Lynn R Webster & Robert J Israel. (2018) Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain. Journal of Pain Research 11, pages 1503-1510.
Read now
Read now
Jermaine D. Jones, Adam Bisaga, Verena E. Metz, Jeanne M. Manubay, Shanthi Mogali, Roberto Ciccocioppo, Gabriela Madera, Molly Doernberg & Sandra D. Comer. (2018) The PPARγ Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety. Journal of Psychoactive Drugs 50:5, pages 390-401.
Read now
Read now
Benjamin J. Malcolm, Martin Polanco & Joseph P. Barsuglia. (2018) Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine. Journal of Psychoactive Drugs 50:3, pages 256-265.
Read now
Read now
Thomas Kingsley Brown & Kenneth Alper. (2018) Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse 44:1, pages 24-36.
Read now
Read now
Geoffrey E. Noller, Chris M. Frampton & Berra Yazar-Klosinski. (2018) Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse 44:1, pages 37-46.
Read now
Read now
Matthew J. Erlendson, Nicole D’Arcy, Ellen M. Encisco, Jeffrey J. Yu, Lorena Rincon-Cruz, Gary Peltz, J. David Clark & Larry F. Chu. (2017) Palonosetron and hydroxyzine pre-treatment reduces the objective signs of experimentally-induced acute opioid withdrawal in humans: a double-blinded, randomized, placebo-controlled crossover study. The American Journal of Drug and Alcohol Abuse 43:1, pages 78-86.
Read now
Read now
Lynn Webster, Peter Hjelmström, Michael Sumner & Erik W. Gunderson. (2016) Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial. Journal of Addictive Diseases 35:4, pages 325-338.
Read now
Read now
Darika Saingam, Sawitri Assanangkornchai, Alan F. Geater & Sanguan Lerkiatbundit. (2016) Factor Analytical Investigation of Krathom (Mitragyna speciosa Korth.) Withdrawal Syndrome in Thailand. Journal of Psychoactive Drugs 48:2, pages 76-85.
Read now
Read now
Farzaneh Tabassomi, Mehran Zarghami, Mohammad-Reza Shiran, Samaneh Farnia & Mohsen Davoodi. (2016) Opium tincture versus methadone syrup in management of acute raw opium withdrawal: A randomized, double-blind, controlled trial. Journal of Addictive Diseases 35:1, pages 8-14.
Read now
Read now
Lynn R Webster, Darren M Brenner, Andrew C Barrett, Craig Paterson, Enoch Bortey & William P Forbes. (2015) Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. Journal of Pain Research 8, pages 771-780.
Read now
Read now
Martin E Hale, Charles Laudadio, Ronghua Yang, Arvind Narayana & Richard Malamut. (2015) Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain. Journal of Pain Research 8, pages 623-636.
Read now
Read now
Bansri Desai, Erin Freeman, Ellen Huang, Anna Hung, Edward Knapp, Ian M Breunig, Mary L McPherson & Fadia T Shaya. (2014) Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy. Expert Review of Clinical Pharmacology 7:2, pages 203-209.
Read now
Read now
Martin E Hale, Srinivas R Nalamachu, Arif Khan & Michael Kutch. (2013) Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain. Journal of Pain Research 6, pages 319-329.
Read now
Read now
R Douglas Bruce, David E Moody, Frederick L Altice, Marc N Gourevitch & Gerald H Friedland. (2013) A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Review of Clinical Pharmacology 6:3, pages 249-269.
Read now
Read now
R. Douglas Bruce, David E. Moody, Diane Chodkowski, Laurie Andrews, Wenfang B. Fang, Jerdravee Morrison, Theresa L. Parsons & Gerald H. Friedland. (2013) Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. The American Journal of Drug and Alcohol Abuse 39:2, pages 80-85.
Read now
Read now
Jermaine D. Jones, Taylor Speer, Sandra D. Comer, Stephen Ross, John Rotrosen & Malcolm S. Reid. (2013) Opioid-Like Effects of the Neurokinin 1 Antagonist Aprepitant in Patients Maintained on and Briefly Withdrawn from Methadone. The American Journal of Drug and Alcohol Abuse 39:2, pages 86-91.
Read now
Read now
Paolo Mannelli, Kathleen Peindl, Li-Tzy Wu, Ashwin A. Patkar & David A. Gorelick. (2012) The Combination Very Low-Dose Naltrexone–Clonidine in the Management of Opioid Withdrawal. The American Journal of Drug and Alcohol Abuse 38:3, pages 200-205.
Read now
Read now
Mehran Zarghami, Babak Masoum & Mohammad-Reza Shiran. (2012) Tramadol versus Methadone for Treatment of Opiate Withdrawal: A Double-Blind, Randomized, Clinical Trial. Journal of Addictive Diseases 31:2, pages 112-117.
Read now
Read now
Walter Ling, Larissa Mooney, Min Zhao, Suzanne Nielsen, Matthew Torrington & Karen Miotto. (2011) Selective review and commentary on emerging pharmacotherapies for opioid addiction. Substance Abuse and Rehabilitation 2, pages 181-188.
Read now
Read now
LuisM. Carcoba, ArturoE. Contreras, Antonio Cepeda-Benito & MaryW. Meagher. (2011) Negative Affect Heightens Opiate Withdrawal-Induced Hyperalgesia in Heroin Dependent Individuals. Journal of Addictive Diseases 30:3, pages 258-270.
Read now
Read now
Howard S Smith. (2011) Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing. Expert Opinion on Pharmacotherapy 12:7, pages 1111-1125.
Read now
Read now
Sherwyn Schwartz, Mila Etropolski, Douglas Y. Shapiro, Akiko Okamoto, Robert Lange, Juergen Haeussler & Christine Rauschkolb. (2011) Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Current Medical Research and Opinion 27:1, pages 151-162.
Read now
Read now
Farhad Safari, Kamran Mottaghi, Saeed Malek & Alireza Salimi. (2010) Effect of Ultra-Rapid Opiate Detoxification on Withdrawal Syndrome. Journal of Addictive Diseases 29:4, pages 449-454.
Read now
Read now
Nathaniel Katz, Martin Hale, David Morris & Joseph Stauffer. (2010) Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules in Patients with Chronic Osteoarthritis Pain. Postgraduate Medicine 122:4, pages 112-128.
Read now
Read now
Keith A. Candiotti & Melvin C. Gitlin. (2010) Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?. Current Medical Research and Opinion 26:7, pages 1677-1684.
Read now
Read now
Craig T Hartrick. (2010) Tapentadol immediate-release for acute pain. Expert Review of Neurotherapeutics 10:6, pages 861-869.
Read now
Read now
Katri Elina Clemens & Gerd Mikus. (2010) Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain. Expert Opinion on Pharmacotherapy 11:2, pages 297-310.
Read now
Read now
Martin Hale, David Upmalis, Akiko Okamoto, Claudia Lange & Christine Rauschkolb. (2009) Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Current Medical Research and Opinion 25:5, pages 1095-1104.
Read now
Read now
O Löwenstein, P Leyendecker, M Hopp, U Schutter, PD Rogers, R Uhl, S Bond, W Kremers, T Nichols, B Krain & K Reimer. (2009) Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opinion on Pharmacotherapy 10:4, pages 531-543.
Read now
Read now
Lauren M. Jansson, Janet A. Dipietro, Martha Velez, Andrea Elko, Heather Knauer & Katie T. Kivlighan. (2009) Maternal methadone dosing schedule and fetal neurobehaviour. The Journal of Maternal-Fetal & Neonatal Medicine 22:1, pages 29-35.
Read now
Read now
Paolo Mannelli, Ashwin A Patkar, Kathleen Peindl, Edward Gottheil, Li-Tzy Wu & David A Gorelick. (2009) Early Outcomes Following Low Dose Naltrexone Enhancement of Opioid Detoxification. American Journal on Addictions 18:2, pages 109-116.
Read now
Read now
Lauren M. Jansson, Janet A. Dipietro, Andrea Elko & Martha Velez. (2007) Maternal vagal tone change in response to methadone is associated with neonatal abstinence syndrome severity in exposed neonates. The Journal of Maternal-Fetal & Neonatal Medicine 20:9, pages 677-685.
Read now
Read now
Elinore F. McCance-Katz, Petrie M. Rainey, Patrick Smith, Gene D. Morse, Gerald Friedland, Beth Boyarsky, Marc Gourevitch & Peter Jatlow. (2006) Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Delavirdine. American Journal on Addictions 15:1, pages 23-34.
Read now
Read now
Edward V. Nunes, Jami L. Rothenberg, Maria A. Sullivan, Kenneth M. Carpenter & Herbert D. Kleber. (2006) Behavioral Therapy to Augment Oral Naltrexone for Opioid Dependence: A Ceiling on Effectiveness?. The American Journal of Drug and Alcohol Abuse 32:4, pages 503-517.
Read now
Read now
Claudia Sannibale, Claudia Sannibale, Lisa Fucito, Claudia Sannibale, Lisa Fucito, Danny O'connor, Claudia Sannibale, Lisa Fucito, Danny O'connor, Kenneth Curry, Claudia Sannibale, Lisa Fucito, Danny O'connor & Kenneth Curry. (2005) Process evaluation of an out-patient detoxification service. Drug and Alcohol Review 24:6, pages 475-481.
Read now
Read now
Tom Palmstierna. (2004) Effects of a High-Dose, Fast Tapering Buprenorphine Detoxification Program on Symptom Relief and Treatment Retention. Journal of Psychoactive Drugs 36:2, pages 273-277.
Read now
Read now
Elinore F. McCance-Katz. (2004) Office-Based Buprenorphine Treatment for Opioid-Dependent Patients. Harvard Review of Psychiatry 12:6, pages 321-338.
Read now
Read now
Joseph Westermeyer, Ilhan Yargic & Paul Thuras. (2004) Michigan Assessment-Screening Test for Alcohol and Drugs (MAST/AD): Evaluation in a Clinical Sample. American Journal on Addictions 13:2, pages 151-162.
Read now
Read now
Jiri Modestin, Peter J. Lipp, Peter Rüesch, Joseph Ha¨ttenschwiler & Daniel Hell. (2003) A comparative naturalistic study on opiates withdrawal. Journal of Substance Use 8:4, pages 238-242.
Read now
Read now
Robert Ali, Peter Thomas, Jason White, Catherine McGregor, Catherine Danz, Linda Gowing, Amanda Stegink & Peter Athanasos. (2003) Antagonist-precipitated heroin withdrawal under anaesthetic prior to maintenance naltrexone treatment: determinants of withdrawal severity. Drug and Alcohol Review 22:4, pages 425-431.
Read now
Read now
DonaldR. Wesson & Walter Ling. (2003) The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs 35:2, pages 253-259.
Read now
Read now
Paolo Mannelli, Edward Gottheil, Antonio Buonanno & Sergio
De Risio. (2003) Use of Very Low-Dose Naltrexone During Opiate Detoxification. Journal of Addictive Diseases 22:2, pages 63-70.
Read now
Read now
Stephen Strobbe, Kirk J. Brower & Luke W. Galen. (2003) Predicting Completion of Outpatient Opioid Detoxification with Clonidine. American Journal on Addictions 12:3, pages 260-269.
Read now
Read now
Jill Williams & Douglas M. Ziedonis. (2003) Naltrexone-Bupropion Combination Therapy for Protracted Abstinence Dysphoria. American Journal on Addictions 12:3, pages 270-272.
Read now
Read now
Judith S. Rose, Marc Branchey, Leah Wallach & Laure Buydens-Branchey. (2003) Effects of Buspirone in Withdrawal from Opiates. American Journal on Addictions 12:3, pages 253-259.
Read now
Read now
Joseph Westermeyer, Ross Crosby & Sean Nugent. (1998) The Minnesota Substance Abuse Problems Scale: Psychometric Analysis and Validation in a Clinical Population. American Journal on Addictions 7:1, pages 24-34.
Read now
Read now
Calle Eklund, Arto J. Hiltunen, Lennart Melin & Stefan Borg. (1997) Patient Perceptions of Psychological and Physiological Withdrawal Symptoms and Positive Factors Associated with Gradual Withdrawal from Methadone Maintenance Treatment: A Prospective Study. Substance Use & Misuse 32:11, pages 1599-1618.
Read now
Read now
Calle Eklund, Arto J. Hiltunen, Lennart Melin & Stefan Borg. (1997) Research Note: Abstinence Fear in Methadone Maintenance Withdrawal: A Possible Obstacle for Getting off Methadone. Substance Use & Misuse 32:6, pages 779-792.
Read now
Read now
Frances Rudnick Levin, Marian W. Fischman, Ingrid Connerney & Richard W. Foltin. (1997) A Protocol to Switch High-Dose, Methadone-Maintained Subjects to Buprenorphine. American Journal on Addictions 6:2, pages 105-116.
Read now
Read now
Marc I Rosen, Thomas J McMahon, Arthur Margolin, Tirath S Gill, Scott W Woods, H. Rowland Pearsall, Mary Jeanne Kreek & Thomas R Kosten. (1995) Reliability of Sequential Naloxone Challenge Tests. The American Journal of Drug and Alcohol Abuse 21:4, pages 453-467.
Read now
Read now
Leonard Handelsman, Marvin J. Aronson, Robert Ness, Kenneth J. Cochrane & Philip D. Kanof. (1992) The Dysphoria of Heroin Addiction. The American Journal of Drug and Alcohol Abuse 18:3, pages 275-287.
Read now
Read now
Articles from other publishers (337)
Christopher R. Nicholas, David M. HortonJulia MalickiAmelia BaltesPaul R. HutsonRandall T. Brown. (2023) Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings. Psychedelic Medicine.
Crossref
Crossref
Mark K. Greenwald, Katharina L. Wiest, Barbara R. Haight, Celine M. Laffont & Yue Zhao. (2023) Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder. Harm Reduction Journal 20:1.
Crossref
Crossref
Orrin D. Ware, Jennifer D. Ellis, Eric C. Strain, Denis G. Antoine, Suky Martinez & Cecelia L. Bergeria. (2023) Increases in primary opioid use disorder diagnoses co-occurring with anxiety or depressive disorder diagnoses in mental health treatment in the United States, 2015–2019. Drug and Alcohol Dependence 253, pages 111022.
Crossref
Crossref
Christina Abdel Shaheed, Rowena Ivers, Lisa Vizza, Andrew McLachlan, Patrick J Kelly, Fiona Blyth, Fiona Stanaway, Philip James Clare, Rachel Thompson, Thomas Lung, Louisa Degenhardt, Sharon Reid, Bradley Martin, Michael Wright, Rawa Osman, Simon French, Kirsten McCaffery, Gabrielle Campbell, Hazel Jenkins, Stephanie Mathieson, Monika Boogs, Jarrod McMaugh, Carol Bennett & Christopher Maher. (2023) Clinical Observation, Management and Function Of low back pain Relief Therapies (COMFORT): A cluster randomised controlled trial protocol. BMJ Open 13:11, pages e075286.
Crossref
Crossref
Sergi Ferré, John W Winkelman, Diego García-Borreguero, Annabelle M Belcher, Joy H Chang & Christopher J Earley. (2023) Restless legs syndrome, neuroleptic-induced akathisia, and opioid-withdrawal restlessness: shared neuronal mechanisms?. SLEEP.
Crossref
Crossref
Douglas H. Fernald, Donald E. Nease, John M. Westfall, Bethany M. Kwan, L. Miriam Dickinson, Ben Sofie, Cory Lutgen, Jennifer K. Carroll, David Wolff, Lori Heeren, Maret Felzien & Linda Zittleman. (2023) A randomized, parallel group, pragmatic comparative-effectiveness trial comparing medication-assisted treatment induction methods in primary care practices: The HOMER study protocol. PLOS ONE 18:9, pages e0290388.
Crossref
Crossref
Robert H. Spencer, Catherine Munera, Megan J. Shram & Frédérique Menzaghi. (2023) Assessment of the physical dependence potential of difelikefalin: Randomized placebo‐controlled study in patients receiving hemodialysis. Clinical and Translational Science 16:9, pages 1559-1568.
Crossref
Crossref
J. Douglas Bremner. (2023) Vagal Nerve Stimulation for Patients With Stress-Related Psychiatric Disorders and Addictions. Journal of Health Service Psychology 49:3, pages 129-135.
Crossref
Crossref
Toby M. Maher, Cristina Avram, Enoch Bortey, Simon P. Hart, Nikhil Hirani, Philip L. Molyneux, Joanna C. Porter, Jaclyn A. Smith & Thomas Sciascia. (2023) Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis. NEJM Evidence 2:8.
Crossref
Crossref
Kathryn Date, Bronwen Williams, Judith Cohen, Nazia Chaudhuri, Sabrina Bajwah, Mark Pearson, Irene Higginson, John Norrie, Catriona Keerie, Sharon Tuck, Peter Hall, David Currow, Marie Fallon & Miriam Johnson. (2023) Modified-release morphine or placebo for chronic breathlessness: the MABEL trial protocol. ERJ Open Research 9:4, pages 00167-2023.
Crossref
Crossref
William H. Craft, Hwasoo Shin, Allison N. Tegge, Diana R. Keith, Liqa N. Athamneh, Jeffrey S. Stein, Marco A. R. Ferreira, Howard D. Chilcoat, Anne Le Moigne, Angela DeVeaugh‐Geiss & Warren K. Bickel. (2023) Long‐term recovery from opioid use disorder: recovery subgroups, transition states and their association with substance use, treatment and quality of life. Addiction 118:5, pages 890-900.
Crossref
Crossref
Stephanie Paula Elisabeth Guillery, Sven Reiners, Marius Fahrner, Sören Enge, Rainer Hellweg, Hagen Kunte & Golo Kronenberg. (2023) The switching process from buprenorphine sublingual tablets to the monthly buprenorphine subcutaneous depot injection in opioid dependent patients. Addiction Biology 28:5.
Crossref
Crossref
Diana R. Keith, Allison N. Tegge, Jeffrey S. Stein, Liqa N. Athamneh, William H. Craft, Howard D. Chilcoat, Anne Le Moigne, Angela DeVeaugh-Geiss & Warren K. Bickel. (2023) Struggling With Recovery From Opioids: Who Is at Risk During COVID-19?. Journal of Addiction Medicine 17:3, pages e156-e163.
Crossref
Crossref
Miranda G. Greiner, Matisyahu Shulman, Onumara Opara, Kenzie Potter, Delia C. Voronca, Hiwot M. Tafessu, Kathryn Hefner, Amy Hamilton, Christina Scheele, Rachel Ho, Lauren Dresser, Eve Jelstrom, Marc Fishman, Udi E. Ghitza, John Rotrosen, Edward V. Nunes & Adam Bisaga. (2023) Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study. Contemporary Clinical Trials 128, pages 107148.
Crossref
Crossref
Kelly E. Dunn, H. Elizabeth Bird, Cecilia L. Bergeria, Orrin D. Ware, Eric C. Strain & Andrew S. Huhn. (2023) Operational definition of precipitated opioid withdrawal. Frontiers in Psychiatry 14.
Crossref
Crossref
Ahmet O Ceceli, Yuefeng Huang, Greg Kronberg, Pias Malaker, Pazia Miller, Sarah G King, Pierre-Olivier Gaudreault, Natalie McClain, Lily Gabay, Devarshi Vasa, Jeffrey H Newcorn, Defne Ekin, Nelly Alia-Klein & Rita Z Goldstein. (2023) Common and distinct fronto-striatal volumetric changes in heroin and cocaine use disorders. Brain 146:4, pages 1662-1671.
Crossref
Crossref
Bryan McCarthy. (2023) Christianity and Psychedelic Medicine: A Pastoral Approach. Christian bioethics: Non-Ecumenical Studies in Medical Morality 29:1, pages 31-57.
Crossref
Crossref
Annabelle M. Belcher, Thomas O. Cole, Ebonie Massey, Amy S. Billing, Michael Wagner, William Wooten, David H. Epstein, Stephen W. Hoag, Emerson M. Wickwire, Aaron D. Greenblatt, Luana Colloca, John Rotrosen, Lawrence Magder, Eric Weintraub, Eric D. Wish & Ted J. Kaptchuk. (2023) Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder. JAMA Network Open 6:4, pages e237099.
Crossref
Crossref
John W. Winkelman. (2023)
Opioids and restless legs syndrome: a double-edged swordCommentary on McCarter SJ, Labott JR, Mazumder MK, et al. Emergence of restless legs syndrome during opioid discontinuation.
J Clin Sleep Med
. 2023;19(4):741–748. doi:10.5664/jcsm.10436
. Journal of Clinical Sleep Medicine 19:4, pages 641-642.
Crossref
Crossref
Yun-Hsuan Chen, Jie Yang, Hemmings Wu, Kevin T. Beier & Mohamad Sawan. (2023) Challenges and future trends in wearable closed-loop neuromodulation to efficiently treat methamphetamine addiction. Frontiers in Psychiatry 14.
Crossref
Crossref
Rebecca E. Stewart, Nicholas C. Cardamone, Allison Schachter, Chloe Becker, James R. McKay & Emily M. Becker-Haimes. (2023) A systematic review of brief, freely accessible, and valid self-report measures for substance use disorders and treatment. Drug and Alcohol Dependence 243, pages 109729.
Crossref
Crossref
Ahmet O. Ceceli, Sarah G. King, Natalie McClain, Nelly Alia-Klein & Rita Z. Goldstein. (2023) The Neural Signature of Impaired Inhibitory Control in Individuals with Heroin Use Disorder. The Journal of Neuroscience 43:1, pages 173-182.
Crossref
Crossref
Helen M Poole, Bernhard Frank, Emma Begley, Aimee Woods, Andreia Ramos-Silva, Mike Merriman, Roisin McCulough & Catharine Montgomery. (2023) Feasibility study of a Behavioural Intervention for Opioid Reduction (BIOR) for patients with chronic non-cancer pain in primary care: a protocol. BMJ Open 13:1, pages e065646.
Crossref
Crossref
Rebecca C. Rossom, A. Lauren Crain, Patrick J. O'Connor, Eric Wright, Irina V. Haller, Stephanie A. Hooker, JoAnn M. Sperl-Hillen, Anthony Olson, Katrina Romagnoli, Leif Solberg, Steven P. Dehmer, Jacob Haapala, Caitlin Borgert-Spaniol, Lorraine Tusing, Jule Muegge, Clayton Allen, Heidi Ekstrom, Kristen Huntley, Jennifer McCormack & Gavin Bart. (2023) Design of a pragmatic clinical trial to improve screening and treatment for opioid use disorder in primary care. Contemporary Clinical Trials 124, pages 107012.
Crossref
Crossref
George F. Koob, Michael A. Arends, Mandy Mccracken & Michel Le Moal. 2023. Opioids. Opioids
1
400
.
A. Benjamin Srivastava, Frances R. Levin & Edward V. Nunes. 2020. Tasman’s Psychiatry. Tasman’s Psychiatry
1
28
.
Joao P. De Aquino, Anees Bahji, Oscar Gómez & Mehmet Sofuoglu. (2022) Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. Drug and Alcohol Dependence 241, pages 109702.
Crossref
Crossref
Celine M. Laffont, Eliford Ngaimisi, Mathangi Gopalakrishnan, Vijay Ivaturi, Malcolm Young, Mark K. Greenwald & Christian Heidbreder. (2022) Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder. Frontiers in Pharmacology 13.
Crossref
Crossref
Amber N. Edinoff, Natalie W. Wu, Catherine A. Nix, Bryce Bonin, Rama Mouhaffel, Stephen Vining, William Gibson, Elyse M. Cornett, Kevin S. Murnane, Adam M. Kaye & Alan D. Kaye. (2022) Historical Pathways for Opioid Addiction, Withdrawal with Traditional and Alternative Treatment Options with Ketamine, Cannabinoids, and Noribogaine: A Narrative Review. Health Psychology Research 10:4.
Crossref
Crossref
Mohammadali Nikoo, Kiana Kianpoor, Nooshin Nikoo, Sanam Javidanbardan, Alireza Kazemi, Fiona Choi, Marc Vogel, Ali Gholami, Saeed Tavakoli, James S. H. Wong, Ehsan Moazen‐Zadeh, Reza Givaki, Majid Jazani, Fatemeh Mohammadian, Nader Markazi Moghaddam, Christian Schütz, Kerry Jang, Shahin Akhondzadeh & Michael Krausz. (2022) Opium tincture versus methadone for opioid agonist treatment: a randomized controlled trial. Addiction.
Crossref
Crossref
Alice Bruneau, Clarice Poirier, Mélanie Bérubé, Aline Boulanger, Céline Gélinas, Line Guénette, Anaïs Lacasse, David Lussier, Yannick Tousignant-Laflamme, M. Gabrielle Pagé & Marc O. Martel. (2022) French-Canadian Translation and Cultural Adaptation of the Clinical Opiate Withdrawal Scale: The COWS-FC. The Canadian Journal of Psychiatry 67:9, pages 701-711.
Crossref
Crossref
Kristine E. Torres‐Lockhart, Tiffany Y. Lu, Melissa B. Weimer, Melissa R. Stein & Chinazo O. Cunningham. (2022) Clinical Management of Opioid Withdrawal. Addiction 117:9, pages 2540-2550.
Crossref
Crossref
David A. Gorelick. (2022) Kratom: Substance of Abuse or Therapeutic Plant?. Psychiatric Clinics of North America 45:3, pages 415-430.
Crossref
Crossref
Irene Pericot-Valverde, Angelica Perez, Moonseong Heo, Ashley Coleman, Erik Ortiz, Krupa Merchant, Trish Melling & Alain Litwin. (2022) Rationale, design, and methodology of a randomized pilot trial of an integrated intervention combining computerized behavioral therapy and recovery coaching for people with opioid use disorder: The OVERCOME study. Contemporary Clinical Trials Communications 28, pages 100918.
Crossref
Crossref
Katherine Z. Isoardi, Lachlan Parker, Keith Harris, Stephen Rashford & Geoffrey K. Isbister. (2022) Acute Opioid Withdrawal Following Intramuscular Administration of Naloxone 1.6 mg: A Prospective Out-Of-Hospital Series. Annals of Emergency Medicine 80:2, pages 120-126.
Crossref
Crossref
Andrew S. Huhn, Patrick H. FinanCharlene E. GamaldoAlexis S. Hammond, Annie UmbrichtCecilia L. Bergeria, Eric C. StrainKelly E. Dunn. (2022) Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. Science Translational Medicine 14:650.
Crossref
Crossref
Peter Uhrbrand, Mikkel Mylius Rasmussen, Simon Haroutounian & Lone Nikolajsen. (2022) Shared decision-making approach to taper postoperative opioids in spine surgery patients with preoperative opioid use: a randomized controlled trial. Pain 163:5, pages e634-e641.
Crossref
Crossref
William H. Craft, Allison N. Tegge, Diana R. Keith, Hwasoo Shin, Jacob Williams, Liqa N. Athamneh, Jeffrey S. Stein, Howard D. Chilcoat, Anne Le Moigne, Angela DeVeaugh-Geiss & Warren K. Bickel. (2022) Recovery from opioid use disorder: A 4-year post-clinical trial outcomes study. Drug and Alcohol Dependence 234, pages 109389.
Crossref
Crossref
Ling Ling Choo, Muhammad Muhsin Ahmad Zahari, Seng Kit Choy, Naemah Abdul Rahim & Rusdi Abd Rashid. (2022) The Prevalence and Psychosocial Correlates of Ketum (Mitragyna speciosa) Use among Individuals on Methadone Maintenance Therapy Programme in Hospital Taiping, Malaysia. Healthcare 10:4, pages 746.
Crossref
Crossref
Saeed Shoja Shafti. (2022) Methadone Contrasted with Acetaminophen Codeine Plus Clonidine: An
Inpatient Pilot Study. Current Psychopharmacology 11:1, pages 43-49.
Crossref
Crossref
Douglas L. Gourlay, Howard A. Heit & Andrew J. Smith. 2022. Clinical Pain Management. Clinical Pain Management
407
418
.
E. Weisshaar, J.C. Szepietowski, J.D. Bernhard, H. Hait, F.J. Legat, L. Nattkemper, A. Reich, B. Sadoghi, T.R. Sciascia, C. Zeidler, G. Yosipovitch & S. Ständer. (2021) Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open‐label extension phase. Journal of the European Academy of Dermatology and Venereology 36:3, pages 453-461.
Crossref
Crossref
Biswadip Chatterjee, Raka Jain, Nishtha Chawla & Rahul Raghav. (2022) Serum Corticotrophin Releasing Factor (CRF) and its correlation with stress and craving in detoxified opioid-dependent subjects. Asian Journal of Psychiatry 68, pages 102964.
Crossref
Crossref
Wenhui Li, Jin Huang, Nan Zhang, Kathrin Weidacker, Jun Li, Valerie Voon, Chuansheng Wang & Chencheng Zhang. (2022) Modulation of Attentional Bias to Drug and Affective Cues by Therapeutic and Neuropsychological Factors in Patients With Opioid Use Disorder on Methadone Maintenance Therapy. Frontiers in Psychiatry 12.
Crossref
Crossref
Aleksandra Dickov. (2022) Insomnia in addictive diseases and treatment of insomnia in opiate withdrawal crisis. Galenika Medical Journal 1:3, pages 14-21.
Crossref
Crossref
Thomas Knuijver, Arnt Schellekens, Maarten Belgers, Rogier Donders, Toon van Oosteren, Kees Kramers & Robbert Verkes. (2021) Safety of ibogaine administration in detoxification of opioid‐dependent individuals: a descriptive open‐label observational study. Addiction 117:1, pages 118-128.
Crossref
Crossref
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
451
536
.
Fatemeh Chalabianloo, Lars Thore Fadnes, Gudrun Høiseth, Christian Ohldieck, Jørn Henrik Vold, Christer Aas, Else-Marie Løberg, Kjell Arne Johansson & Jørgen G. Bramness. (2021) Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway. Substance Abuse Treatment, Prevention, and Policy 16:1.
Crossref
Crossref
Brent Boyett, Katharina Wiest, Lori D. McLeod, Lauren M. Nelson, Warren K. Bickel, Susan M. Learned, Christian Heidbreder, Paul J. Fudala, Anne Le Moigne & Yue Zhao. (2021) Assessment of craving in opioid use disorder: Psychometric evaluation and predictive validity of the opioid craving VAS. Drug and Alcohol Dependence 229, pages 109057.
Crossref
Crossref
Michael Soyka. (2021) Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review. Frontiers in Pharmacology 12.
Crossref
Crossref
Siddharth Sarkar, Renu Singh, Arundhati Sharma, Muzaffar A Pandit, Ranjan Gupta, Deepika Singhal, Raka Jain & Yatan P Balhara. (2021) Association of Serotonergic Pathway Gene Polymorphisms With Behavioral Parameters in Patients With Opioid Dependence. Cureus.
Crossref
Crossref
Christine Timko, Kurt Kroenke, Andrea Nevedal, Mai Chee Lor, Elizabeth Oliva, Karen Drexler, Friedhelm Sandbrink & Katherine Hoggatt. (2021) Development and field testing of primary care screening tools for harms of long-term opioid therapy continuation and tapering to discontinuation: a study protocol. BMJ Open 11:10, pages e053524.
Crossref
Crossref
Darren M. Brenner, Neal E. Slatkin, Nancy Stambler, Robert J. Israel & Paul H. Coluzzi. (2021) The influence of brain metastases on the central nervous system effects of methylnaltrexone: a post hoc analysis of 3 randomized, double-blind studies. Supportive Care in Cancer 29:9, pages 5209-5218.
Crossref
Crossref
Victoria D. Powell, Jack M. Rosenberg, Avani Yaganti, Claire Garpestad, Pooja Lagisetty, Carol Shannon & Maria J. Silveira. (2021) Evaluation of Buprenorphine Rotation in Patients Receiving Long-term Opioids for Chronic Pain. JAMA Network Open 4:9, pages e2124152.
Crossref
Crossref
Alice Bruneau, Leah Frimerman, Maria Verner, Amanda Sirois, Catherine Fournier, Katherine Scott, Jordi Perez, Yoram Shir & Marc O. Martel. (2021) Day-to-day opioid withdrawal symptoms, psychological distress, and opioid craving in patients with chronic pain prescribed opioid therapy. Drug and Alcohol Dependence 225, pages 108787.
Crossref
Crossref
Edward V. NunesJr.Jr., Jennifer M. ScodesMartina PavlicovaJoshua D. LeePatricia NovoAimee N.C. CampbellJohn Rotrosen. (2021) Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment. American Journal of Psychiatry 178:7, pages 660-671.
Crossref
Crossref
Solomon S. Liao, Neal E. Slatkin & Nancy Stambler. (2021) The Influence of Age on Central Effects of Methylnaltrexone in Patients with Opioid-Induced Constipation. Drugs & Aging 38:6, pages 503-511.
Crossref
Crossref
Casper J. H. Wolf, Harmen Beurmanjer, Boukje A. G. Dijkstra, Alexander C. Geerlings, Marcia Spoelder, Judith R. Homberg & Arnt F. A. Schellekens. (2021) Characterization of the GHB Withdrawal Syndrome. Journal of Clinical Medicine 10:11, pages 2333.
Crossref
Crossref
Gail D'Onofrio, Kathryn F. Hawk, Andrew A. Herring, Jeanmarie Perrone, Ethan Cowan, Ryan P. McCormack, James Dziura, R. Andrew Taylor, Edouard Coupet, E. Jennifer Edelman, Michael V. Pantalon, Patricia H. Owens, Shara H. Martel, Patrick G. O'Connor, Paul Van Veldhuisen, Nicholas DeVogel, Kristen Huntley, Sean M. Murphy, Michelle R. Lofwall, Sharon L. Walsh & David A. Fiellin. (2021) The design and conduct of a randomized clinical trial comparing emergency department initiation of sublingual versus a 7-day extended-release injection formulation of buprenorphine for opioid use disorder: Project ED Innovation. Contemporary Clinical Trials 104, pages 106359.
Crossref
Crossref
Esben Bolvig Mark, Jens Brøndum Frøkjær, Tine Maria Hansen, Rasmus Bach Nedergaard & Asbjørn Mohr Drewes. (2021) Although tapentadol and oxycodone both increase colonic volume, tapentadol treatment resulted in softer stools and less constipation: a mechanistic study in healthy volunteers. Scandinavian Journal of Pain 21:2, pages 406-414.
Crossref
Crossref
Sara L. Kroll, Julian F. Thayer, DeWayne P. Williams, Daniela M. Pfabigan, Markus R. Baumgartner, Claus Lamm & Boris B. Quednow. (2021) Chronic non‐medical prescription opioid use and empathy for pain: Does pain make the difference?. Psychophysiology 58:4.
Crossref
Crossref
Irene Pericot‐Valverde, Lior Rennert, Moonseong Heo, Matthew J. Akiyama, Briana L. Norton, Linda Agyemang, Brandon Lumsden & Alain H. Litwin. (2020) Rates of perfect self‐reported adherence to direct‐acting antiviral therapy and its correlates among people who inject drugs on medications for opioid use disorder: The PREVAIL study. Journal of Viral Hepatitis 28:3, pages 548-557.
Crossref
Crossref
Samira Abbaszadeh‐Mashkani, Shahanara Sunjida Hoque, Hamid Reza Banafshe & Amir Ghaderi. (2020) The effect of crocin (the main active saffron constituent) on the cognitive functions, craving, and withdrawal syndrome in opioid patients under methadone maintenance treatment. Phytotherapy Research 35:3, pages 1486-1494.
Crossref
Crossref
Henry R Kranzler, Kevin G Lynch, Richard C Crist, Emily Hartwell, Anne Le Moigne, Celine M Laffont & Anne C Andorn. (2021) A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder. International Journal of Neuropsychopharmacology 24:2, pages 89-96.
Crossref
Crossref
Frances R. Levin, John J. Mariani, Martina Pavlicova, C. Jean Choi, Cale Basaraba, Amy L. Mahony, Daniel J. Brooks, Nasir Naqvi & Adam Bisaga. (2021) Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial. Drug and Alcohol Dependence 219, pages 108482.
Crossref
Crossref
Neel Mehta, Neal E. Slatkin, Robert J. Israel & Nancy Stambler. (2023) Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation: a post hoc pooled analysis of two clinical trials. F1000Research 10, pages 891.
Crossref
Crossref
Neel Mehta, Neal E. Slatkin, Robert J. Israel & Nancy Stambler. (2021) Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation: a post hoc pooled analysis of two clinical trials. F1000Research 10, pages 891.
Crossref
Crossref
Hengfen Gong, Yingying Zhang, Qihuan Ren, Zhirong Zhou, Huijing Zhou, Xirong Sun, Chencheng Zhang, Valerie Voon, Min Zhao & Shunying Yu. (2020) The Chinese version of obsessive compulsive drug use scale: validation in outpatient methadone maintenance treatment program. BMC Psychiatry 20:1.
Crossref
Crossref
Troy A. Moore. (2020) Ambulatory detoxification in alcohol use disorder and opioid use disorder. Mental Health Clinician 10:6, pages 307-316.
Crossref
Crossref
Kelly Dunn, Cecilia Bergeria, Andrew S. Huhn & Eric C. Strain. (2020) Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome. Drug and Alcohol Dependence 215, pages 108212.
Crossref
Crossref
Stefan Weisshaar, Laura Brandt, Brigitte Litschauer, Safoura Sheik‐Rezaei, Laura Moser, Günther Nirnberger, Elisabeth Kühberger, Ulrike Bauer, Christa Firbas, Ghazaleh Gouya, Michael Wolzt & Gabriele Fischer. (2020) Dose‐dependent naloxone‐induced morphine withdrawal symptoms in opioid‐dependent males—a double‐blinded, randomized study. British Journal of Clinical Pharmacology 86:8, pages 1610-1619.
Crossref
Crossref
Jack E Henningfield, Jeffrey Gudin, Richard Rauck, Joseph Gimbel, Mary Tagliaferri, Stephen K Doberstein, Carlo Di Fonzo, Lin Lu, Nathaniel Katz, Suresh Siddhanti & Sidney Schnoll. (2020) Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain. Pain Medicine 21:8, pages 1553-1561.
Crossref
Crossref
Jeffrey Gudin, Richard Rauck, Charles Argoff, Eva Agaiby, Joseph Gimbel, Nathaniel Katz, Stephen K Doberstein, Mary Tagliaferri, Margit Tagliaferri, Jeffrey Potts, James Wild, Lin Lu, Suresh Siddhanti, Martin Hale & John Markman. (2020) Long-term Safety and Tolerability of NKTR-181 in Patients with Moderate to Severe Chronic Low Back Pain or Chronic Noncancer Pain: A Phase 3 Multicenter, Open-Label, 52-Week Study (SUMMIT-08 LTS). Pain Medicine 21:7, pages 1347-1356.
Crossref
Crossref
Devika Nair & Fredric O. Finkelstein. (2020) Pruritus as a Patient-Reported Primary Trial End Point in Hemodialysis: Evaluation and Implications. American Journal of Kidney Diseases 76:1, pages 148-151.
Crossref
Crossref
Shanna Babalonis & Sharon L. Walsh. (2020) Therapeutic potential of opioid/cannabinoid combinations in humans: Review of the evidence. European Neuropsychopharmacology 36, pages 206-216.
Crossref
Crossref
Cecilia L. Bergeria, Andrew S. Huhn & Kelly E. Dunn. (2020) The impact of naturalistic cannabis use on self-reported opioid withdrawal. Journal of Substance Abuse Treatment 113, pages 108005.
Crossref
Crossref
Harmen Beurmanjer, J. J. Luykx, B. De Wilde, K. van Rompaey, V. J. A. Buwalda, C. A. J. De Jong, B. A. G. Dijkstra & A. F. A. Schellekens. (2020) Tapering with Pharmaceutical GHB or Benzodiazepines for Detoxification in GHB-Dependent Patients: A Matched-Subject Observational Study of Treatment-as-Usual in Belgium and The Netherlands. CNS Drugs 34:6, pages 651-659.
Crossref
Crossref
Robertas Badaras, Tomas Jovaisa, Indre Lapinskiene & Juozas Ivaskevicius. (2020) Dose Escalation of Naltrexone to Reduce Stress Responses Associated With Opioid Antagonist Induction: A Double-blind Randomized Trial. Journal of Addiction Medicine 14:3, pages 253-260.
Crossref
Crossref
Anna B. KonovaSilvia Lopez-Guzman, Adelya Urmanche, Stephen Ross, Kenway Louie, John Rotrosen & Paul W. Glimcher. (2020) Computational Markers of Risky Decision-making for Identification of Temporal Windows of Vulnerability to Opioid Use in a Real-world Clinical Setting. JAMA Psychiatry 77:4, pages 368.
Crossref
Crossref
. (2020) The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. Journal of Addiction Medicine 14:2S, pages 1-91.
Crossref
Crossref
Laura Brandt, Jermaine D. Jones, Suky Martinez, Jeanne M. Manubay, Shanthi Mogali, Tatiana Ramey, Frances R. Levin & Sandra D. Comer. (2020) Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder. Drug and Alcohol Dependence 208, pages 107859.
Crossref
Crossref
Albert Garcia-Romeu, David J. Cox, Kirsten E. Smith, Kelly E. Dunn & Roland R. Griffiths. (2020) Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic. Drug and Alcohol Dependence 208, pages 107849.
Crossref
Crossref
Steven FishbaneAamir JamalCatherine MuneraWarren WenFrédérique Menzaghi. (2020) A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. New England Journal of Medicine 382:3, pages 222-232.
Crossref
Crossref
Julienne K. Kirk, Tamela Yount, Charlotte T. Boyd, Lisa Cassidy-Vu, Aubry N. Koehler & John G. Spangler. (2020) Launching a Medication-Assisted Treatment in an Outpatient Office-Based Practice. Journal of Primary Care & Community Health 11, pages 215013272094072.
Crossref
Crossref
Nihit Kumar, Michael J Mancino, Jeff D Thostenson, Janette McGaugh & Alison H Oliveto. (2020) Feasibility and Preliminary Efficacy of Isradipine During Outpatient Buprenorphine Stabilization and Detoxification: A Pilot Randomized, Placebo-Controlled Trial. Substance Abuse: Research and Treatment 14, pages 117822182097092.
Crossref
Crossref
Kelly E. Dunn, Elise M. Weerts, Andrew S. Huhn, Jennifer R. Schroeder, David Andrew Tompkins, George E. Bigelow & Eric C. Strain. (2018) Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes. Addiction Biology 25:1.
Crossref
Crossref
Bonnie Huang Hall. 2020. Evaluation and Management of Chronic Pain for Primary Care. Evaluation and Management of Chronic Pain for Primary Care
105
134
.
Ojas Mainkar, Miranda Greiner, Jonathan Avery & Neel Mehta. 2020. Guide to the Inpatient Pain Consult. Guide to the Inpatient Pain Consult
495
518
.
Ojas Mainkar, Miranda Greiner, Jonathan Avery & Neel Mehta. 2020. Guide to the Inpatient Pain Consult. Guide to the Inpatient Pain Consult
167
195
.
Joseph K. Nuamah, Farzan Sasangohar, Madhav Erraguntla & Ranjana K. Mehta. (2019) The past, present and future of opioid withdrawal assessment: a scoping review of scales and technologies. BMC Medical Informatics and Decision Making 19:1.
Crossref
Crossref
Natalia Bienek, Christoph Maier, Miriam Kaisler, Beate Michel-Lauter, Andreas Schwarzer & Christine H Meyer-Frießem. (2019) Intensity of Withdrawal Symptoms During Opioid Taper in Patients with Chronic Pain—Individualized or Fixed Starting Dosage?. Pain Medicine 20:12, pages 2438-2449.
Crossref
Crossref
Kelly E. Dunn, Andrew S. Huhn, Cecilia L. Bergeria, Cassandra D. Gipson & Elise M. Weerts. (2019) Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence. Journal of Pharmacology and Experimental Therapeutics 371:2, pages 422-452.
Crossref
Crossref
Gretchen Hermes, Scott M. Hyman, Nia Fogelman, Thomas R. Kosten & Rajita Sinha. (2019) Lofexidine in Combination With Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A Pilot Randomized, Double‐Blind, Placebo‐Controlled Study. The American Journal on Addictions 28:6, pages 480-488.
Crossref
Crossref
Andrew S Huhn, D Andrew Tompkins, Claudia M Campbell & Kelly E Dunn. (2019) Individuals with Chronic Pain Who Misuse Prescription Opioids Report Sex-Based Differences in Pain and Opioid Withdrawal. Pain Medicine 20:10, pages 1942-1947.
Crossref
Crossref
Caroline A. Arout, Andrew J. Waters, R. Ross MacLean, Peggy Compton & Mehmet Sofuoglu. (2018) Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients. Psychopharmacology 236:10, pages 2857-2866.
Crossref
Crossref
Cecilia L. Bergeria, Andrew S. Huhn, D. Andrew Tompkins, George E. Bigelow, Eric C. Strain & Kelly E. Dunn. (2019) The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal. Drug and Alcohol Dependence 202, pages 111-114.
Crossref
Crossref
Katy Moore, Mindy Magee, Heather Sevinsky, Ming Chang, Susan Lubin, Elsa Myers, Peter Ackerman & Cyril Llamoso. (2019) Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid‐dependent, human immunodeficiency virus seronegative participants. British Journal of Clinical Pharmacology 85:8, pages 1771-1780.
Crossref
Crossref
Jennifer L Koehl, David E Zimmerman & Patrick J Bridgeman. (2019) Medications for management of opioid use disorder. American Journal of Health-System Pharmacy 76:15, pages 1097-1103.
Crossref
Crossref
Abigail Zavod, Sarah C. Akerman, Martha M. Snow, Matt Tierney & Maria A. Sullivan. (2018) Psychoeducational Strategies During Outpatient Transition to Extended-Release Naltrexone for Patients With Opioid Use Disorder. Journal of the American Psychiatric Nurses Association 25:4, pages 272-279.
Crossref
Crossref
Bennett Doughty, Daralyn Morgenson & Tracy Brooks. (2019) Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal. Annals of Pharmacotherapy 53:7, pages 746-753.
Crossref
Crossref
Annabelle M Belcher, Thomas O Cole, Aaron D Greenblatt, Stephen W Hoag, David H Epstein, Michael Wagner, Amy S Billing, Ebonie Massey, Kristen R Hamilton, Zofia K Kozak, Christopher J Welsh, Eric Weintraub, Emerson M Wickwire, Eric D Wish, Ted J Kaptchuk & Luana Colloca. (2019) Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment. BMJ Open 9:6, pages e026604.
Crossref
Crossref
John Markman, Jeffrey Gudin, Richard Rauck, Charles Argoff, Michael Rowbotham, Eva Agaiby, Joseph Gimbel, Nathaniel Katz, Stephen K. Doberstein, Mary Tagliaferri, Lin Lu, Suresh Siddhanti & Martin Hale. (2019) SUMMIT-07: a randomized trial of NKTR-181, a new molecular entity, full mu-opioid receptor agonist for chronic low-back pain. Pain 160:6, pages 1374-1382.
Crossref
Crossref
Ning-Sheng Cai, César Quiroz, Jordi Bonaventura, Alessandro Bonifazi, Thomas O. Cole, Julia Purks, Amy S. Billing, Ebonie Massey, Michael Wagner, Eric D. Wish, Xavier Guitart, William Rea, Sherry Lam, Estefanía Moreno, Verònica Casadó-Anguera, Aaron D. Greenblatt, Arthur E. Jacobson, Kenner C. Rice, Vicent Casadó, Amy H. Newman, John W. Winkelman, Michael Michaelides, Eric Weintraub, Nora D. Volkow, Annabelle M. Belcher & Sergi Ferré. (2019) Opioid–galanin receptor heteromers mediate the dopaminergic effects of opioids. Journal of Clinical Investigation 129:7, pages 2730-2744.
Crossref
Crossref
Carlos Blanco & Nora D Volkow. (2019) Management of opioid use disorder in the USA: present status and future directions. The Lancet 393:10182, pages 1760-1772.
Crossref
Crossref
Mohammadali Nikoo, Ehsan Moazen‐Zadeh, Nooshin Nikoo, Sanam Javidanbardan, Alireza Kazemi, Fiona Choi, Marc Vogel, Ali Gholami, Saeed Tavakoli, Reza Givaki, Majid Jazani, Fatemeh Mohammadian, Nader Markazi Moghaddam, Nasser Goudarzi, Christian Schutz, Kerry Jang, Shahin Akhondzadeh & Michael Krausz. (2019) Comparing opium tincture and methadone for medication‐assisted treatment of patients with opioid use disorder: Protocol for a multicenter parallel group noninferiority double‐blind randomized controlled trial. International Journal of Methods in Psychiatric Research 28:1.
Crossref
Crossref
Sara L. Kroll, DeWayne P. Williams, Martina Thoma, Matthias Staib, Tina M. Binz, Markus R. Baumgartner, Clemens Kirschbaum, Julian F. Thayer & Boris B. Quednow. (2019) Non-medical prescription opioid users exhibit dysfunctional physiological stress responses to social rejection. Psychoneuroendocrinology 100, pages 264-275.
Crossref
Crossref
Alicja Lerner & Michael Klein. (2019) Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development. Brain Communications 1:1.
Crossref
Crossref
John A. RennerJr.Jr. & Mitchell B. Crawford. 2019. Treating Opioid Addiction. Treating Opioid Addiction
89
107
.
Matthew J. Akiyama, Linda Agyemang, Julia H. Arnsten, Moonseong Heo, Brianna L. Norton, Bruce R. Schackman, Benjamin P. Linas & Alain H. Litwin. (2018) Rationale, design, and methodology of a trial evaluating three models of care for HCV treatment among injection drug users on opioid agonist therapy. BMC Infectious Diseases 18:1.
Crossref
Crossref
Sara L. Kroll, Emilija Nikolic, Franziska Bieri, Michael Soyka, Markus R. Baumgartner & Boris B. Quednow. (2018) Cognitive and socio-cognitive functioning of chronic non-medical prescription opioid users. Psychopharmacology 235:12, pages 3451-3464.
Crossref
Crossref
Farid Motlagh, Fatimah Ibrahim, Rusdi Rashid, Niusha Shafiabady, Tahereh Seghatoleslam & Hussain Habil. (2018) Acute effects of methadone on EEG power spectrum and event-related potentials among heroin dependents. Psychopharmacology 235:11, pages 3273-3288.
Crossref
Crossref
Jennifer R. Schroeder, Karran A. Phillips, David H. Epstein, Michelle L. Jobes, Melody A. Furnari, Ashley P. Kennedy, Markus Heilig & Kenzie L. Preston. (2018) Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder. Psychopharmacology 235:10, pages 2957-2966.
Crossref
Crossref
Paolo Mannelli, Marvin Swartz & Li-Tzy Wu. (2018) Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone. The American Journal on Addictions 27:6, pages 471-476.
Crossref
Crossref
G.P. Kurita, J. Højsted & P. Sjøgren. (2018) Tapering off long-term opioid therapy in chronic non-cancer pain patients: A randomized clinical trial. European Journal of Pain 22:8, pages 1528-1543.
Crossref
Crossref
Siddharth Sarkar, Raka Jain, Shanti M. Kethawath, Rishi Gupta & Mukesh Kumar. (2018) Serum BDNF levels in patients with opioid dependence during the early withdrawal period: A case control study. Neuroscience Letters 681, pages 100-104.
Crossref
Crossref
Song Guo, Victoria Manning, Yi Yang, Puay Kee Koh, Edwin Chan, Nurun Nisa de Souza, Pryseley Nkouibert Assam, Rehena Sultana, Ruki Wijesinghe, Julius Pangjaya, Gomathinayagam Kandasami, Christopher Cheok, Kae Meng Lee & Kim Eng Wong. (2018) Lofexidine versus diazepam for the treatment of opioid withdrawal syndrome: A double-blind randomized clinical trial in Singapore. Journal of Substance Abuse Treatment 91, pages 1-11.
Crossref
Crossref
Jennifer S. Love, Jeanmarie Perrone & Lewis S. Nelson. (2018) Should Buprenorphine Be Administered to Patients With Opioid Withdrawal in the Emergency Department?. Annals of Emergency Medicine 72:1, pages 26-28.
Crossref
Crossref
Deborah C. Mash, Linda Duque, Bryan Page & Kathleen Allen-Ferdinand. (2018) Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes. Frontiers in Pharmacology 9.
Crossref
Crossref
Adam Bisaga, Paolo Mannelli, Miao Yu, Narinder Nangia, Christine E. Graham, D. Andrew Tompkins, Thomas R. Kosten, Sarah C. Akerman, Bernard L. Silverman & Maria A. Sullivan. (2018) Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. Drug and Alcohol Dependence 187, pages 171-178.
Crossref
Crossref
Michelle R. Lofwall, Sharon L. Walsh, Edward V. Nunes, Genie L. Bailey, Stacey C. Sigmon, Kyle M. Kampman, Michael Frost, Fredrik Tiberg, Margareta Linden, Behshad Sheldon, Sonia Oosman, Stefan Peterson, Michael Chen & Sonnie Kim. (2018) Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder. JAMA Internal Medicine 178:6, pages 764.
Crossref
Crossref
Tetsuya Hirata, Kaori Koga, Todd A. Johnson, Ryoko Morino, Kazuyuki Nakazono, Shigeo Kamitsuji, Masanori Akita, Maiko Kawajiri, Azusa Kami, Yuria Hoshi, Asami Tada, Kenichi Ishikawa, Maaya Hine, Miki Kobayashi, Nami Kurume, Tomoyuki Fujii, Naoyuki Kamatani & Yutaka Osuga. (2018) Japanese GWAS identifies variants for bust-size, dysmenorrhea, and menstrual fever that are eQTLs for relevant protein-coding or long non-coding RNAs. Scientific Reports 8:1.
Crossref
Crossref
Lynn R. Webster, Srinivas Nalamachu, Bart Morlion, Jyotsna Reddy, Yuko Baba, Tadaaki Yamada & Juan C. Arjona Ferreira. (2018) Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study. Pain 159:5, pages 987-994.
Crossref
Crossref
Larry F. Chu, Tom Rico, Erika Cornell, Hannah Obasi, Ellen M. Encisco, Haley Vertelney, Jamison G. Gamble, Clayton W. Crawford, John Sun, Anna Clemenson, Matthew J. Erlendson, Robin Okada, Ian Carroll & J. David Clark. (2018) Ondansetron does not prevent physical dependence in patients taking opioid medications chronically for pain control. Drug and Alcohol Dependence 183, pages 176-183.
Crossref
Crossref
Neeraj Jain, BS Chavan, Ajeet Sidana & Subhash Das. (2018) Efficacy of buprenorphine and clonidine in opioid detoxification: A hospital- based study. Indian Journal of Psychiatry 60:3, pages 292.
Crossref
Crossref
Kelly E. Dunn, Patrick H. Finan, D. Andrew Tompkins & Eric C. Strain. (2018) Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients. Addictive Behaviors 76, pages 8-14.
Crossref
Crossref
J. Gregory Hobelmann & Michael R. Clark. 2018. Essentials of Pain Medicine. Essentials of Pain Medicine
419
426.e2
.
Jennifer L. Pikard, Sarah Penfold & M. Nadeem Mazhar. 2018. Complex Clinical Conundrums in Psychiatry. Complex Clinical Conundrums in Psychiatry
67
78
.
Mark S. Wallace & Alexander Papp. 2018. Challenging Cases and Complication Management in Pain Medicine. Challenging Cases and Complication Management in Pain Medicine
15
20
.
Pertti Kalevi Heikman, Leea Hellevi Muhonen & Ilkka Antero Ojanperä. (2017) Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine. BMC Psychiatry 17:1.
Crossref
Crossref
Ada W. Chiu, Sofia Contreras, Sangeeta Mehta, Jennifer Korman, Marc M. Perreault, David R. Williamson & Lisa D. Burry. (2017) Iatrogenic Opioid Withdrawal in Critically Ill Patients: A Review of Assessment Tools and Management. Annals of Pharmacotherapy 51:12, pages 1099-1111.
Crossref
Crossref
Jessa Koch, Sarah Ward & Christopher J. Thomas. (2017) Implementation and results of a symptom-triggered opioid withdrawal protocol at a Veterans Affairs medical center. Mental Health Clinician 7:6, pages 282-286.
Crossref
Crossref
E. M. Krupitskii, R. D. Ilyuk, A. D. Mikhailov, K. A. Kazankov, K. V. Rybakova, E. P. Skurat, O. G. Grishina, I. A. Zaplatkin, M. V. Vetrova & N. G. Neznanov. (2017) A Randomized Controlled Study of the Efficacy of Pregabalin in the Treatment of Opiate Withdrawal Syndrome. Neuroscience and Behavioral Physiology 47:9, pages 1094-1101.
Crossref
Crossref
Jermaine D. Jones, Jeanne M. Manubay, Shanthi Mogali, Verena E. Metz, Gabriela Madera, Suky Martinez, Mudassir Mumtaz & Sandra D. Comer. (2017) Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount. Drug and Alcohol Dependence 179, pages 362-369.
Crossref
Crossref
Paula Alves, Célia Sales & Mark Ashworth. (2017) Does outcome measurement of treatment for substance use disorder reflect the personal concerns of patients? A scoping review of measures recommended in Europe. Drug and Alcohol Dependence 179, pages 299-308.
Crossref
Crossref
D. Dupoiron, A. Stachowiak, O. Loewenstein, A. Ellery, W. Kremers, B. Bosse & M. Hopp. (2017) Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study. European Journal of Pain 21:9, pages 1485-1494.
Crossref
Crossref
Larry F. Chu, John Sun, Anna Clemenson, Matthew J. Erlendson, Tom Rico, Erika Cornell, Hannah Obasi, Zahra N. Sayyid, Ellen M. Encisco, Jeff Yu, Jamison G. Gamble, Ian Carroll & J. David Clark. (2017) Ondansetron Does Not Reduce Withdrawal in Patients With Physical Dependence on Chronic Opioid Therapy. Journal of Addiction Medicine 11:5, pages 342-349.
Crossref
Crossref
Verena E Metz, Jermaine D Jones, Jeanne Manubay, Maria A Sullivan, Shanthi Mogali, Andrew Segoshi, Gabriela Madera, Kirk W Johnson & Sandra D Comer. (2017) Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. Neuropsychopharmacology 42:9, pages 1825-1832.
Crossref
Crossref
Displaying 200 of 400 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list